asnglyarg
ngr
motif
cyclic
linear
form
previous
shown
specif
bind
n
select
overexpress
tumor
vasculatur
tumor
cell
howev
previou
version
cyclic
ngr
use
liabl
disulfid
bridg
cystein
residu
may
problemat
liposom
target
due
disulfid
bond
format
adjac
peptid
liposom
surfac
studi
report
design
synthesi
character
novel
cyclic
ngr
contain
peptid
ckngre
contain
disulfid
bridg
ckngre
synthes
good
yield
puriti
attach
fluoresc
report
oregon
green
ckngreog
lysolipidcontain
temperatur
sensit
liposom
ltsl
ident
ckngre
verifi
nmr
mass
spectral
techniqu
vitro
fluoresc
microscopi
evalu
ckngreog
demonstr
bind
activ
uptak
cancer
cell
minim
bind
cancer
cell
ckngreog
ligand
display
greater
affin
cancer
cell
linear
ngr
contain
peptid
affin
cancer
cell
similarli
improv
cyclic
linear
ngr
present
multival
fashion
surfac
ltsl
ckngretarget
ltsl
rapidli
releas
sec
doxorubicin
minim
releas
result
demonstr
abil
synthes
ckngretarget
temperatur
sensit
liposom
lack
disulfid
bridg
suffici
bind
affin
biolog
applic
target
tumorspecif
tumorassoci
antigen
wide
use
paradigm
broad
applic
includ
anticanc
therapi
sitespecif
drug
deliveri
molecular
imag
often
antigen
either
entir
absent
bare
present
normal
cell
correspond
author
matthew
r
dreher
nation
institut
health
rockvil
pike
build
rm
msc
bethesda
md
phone
fax
dreherm
ccnihgov
publish
disclaim
pdf
file
unedit
manuscript
accept
public
servic
custom
provid
earli
version
manuscript
manuscript
undergo
copyedit
typeset
review
result
proof
publish
final
citabl
form
pleas
note
product
process
error
may
discov
could
affect
content
legal
disclaim
appli
journal
pertain
tissu
use
variou
tumorassoci
antigen
target
cancer
therapi
well
document
includ
leukocyt
differenti
antigen
acut
myeloid
leukemia
neuroblastoma
folat
receptor
wide
varieti
human
tumor
antigen
express
angiogen
tumor
vasculatur
particularli
attract
tumorassoci
target
intim
contact
blood
therefor
geograph
access
immedi
follow
intraven
inject
target
agent
wide
use
tumor
vascular
target
includ
integrin
vascular
endotheli
growth
factor
receptor
vegfr
plateletderiv
growth
factor
receptor
pdgfr
n
apn
refer
throughout
focu
studi
angiogen
tumor
vessel
import
element
tumor
growth
metastasi
essenti
transport
metabol
crucial
materi
tumor
cell
also
provid
rout
dissemin
tumor
cell
distal
site
asnglyarg
ngr
peptid
motif
use
target
drug
drugcontain
liposom
tumor
vascular
antigen
result
improv
biodistribut
tumor
therapi
although
linear
ngr
peptid
demonstr
suitabl
biodistribut
efficaci
antitumor
activ
drug
associ
cyclic
form
ngr
report
greater
despit
higher
affin
cyclic
ngr
peptid
prefer
use
linear
ngrcontain
motif
target
liposom
avoid
format
disulfid
bridg
adjac
peptid
liposom
surfac
may
render
ligand
ineffect
object
studi
design
synthes
novel
cyclic
ngr
peptid
contain
disulfid
bridg
evalu
peptid
specif
affin
cancer
cell
linear
ngr
control
peptid
synthes
comparison
goal
synthes
target
lysolipidcontain
temperatur
sensit
liposom
ltsl
imageguid
heatactiv
deliveri
chemotherapeut
solid
tumor
ltsl
mainli
compos
dppc
rapidli
releas
content
clinic
relev
hypertherm
temperatur
small
fraction
lysolipid
eg
mspc
incorpor
lipid
bilay
ltsl
may
combin
focal
hyperthermia
thermal
ablat
select
deliv
encapsul
drug
heat
region
end
synthes
ngrtarget
ltsl
evalu
bind
target
ltsl
cell
well
releas
encapsul
doxorubicin
dox
function
temperatur
ngrtarget
ltsl
potenti
improv
therapeut
efficaci
slow
transit
time
liposom
tumor
vasculatur
improv
drug
releas
improv
total
drug
accumul
tumor
treat
metastat
tumor
subject
hyperthermia
reagent
solvent
anhydr
obtain
sigmaaldrich
mo
use
receiv
unless
otherwis
indic
fmocarg
pbf
oh
suppli
either
novabiochem
ca
chemimpex
intern
inc
il
novapeg
rink
amid
resin
n
n
uronium
hexafluorophosph
hatu
amino
acid
use
studi
purchas
novabiochem
fmocglyrinkamid
mbha
resin
purchas
peptid
intern
ky
hydrat
hobt
purchas
anaspec
ca
oregon
green
og
perchlor
dio
purchas
invitrogen
mspc
dppc
methoxi
polyethylen
glycol
carboxi
polyethylen
glycol
ammonium
salt
dspepeg
ch
cooh
obtain
avanti
polar
lipid
al
h
nmr
c
nmr
spectra
record
use
bruker
mhz
spectromet
oper
mhz
h
mhz
c
respect
mass
spectral
data
record
pesciex
api
appli
biosystem
inc
ca
ultraflex
toftof
bruker
dalton
inc
instrument
purif
peptid
perform
use
prepar
revers
phase
hplc
varian
prostar
model
pda
detector
microsorb
column
mm
analyt
hplc
perform
use
instrument
microsorb
column
mm
human
fibrosarcoma
human
adenocarcinoma
cell
purchas
american
type
cultur
collect
atcc
va
cell
grown
meme
atcc
supplement
fetal
bovin
serum
atcc
iuml
penicillin
streptomycin
invitrogen
cell
grown
cultur
medium
addit
mgml
bovin
insulin
sigmaaldrich
cell
line
maintain
co
incub
cyclic
kngre
ckngre
rink
amid
resin
mmolg
load
wash
dichloromethan
dcm
nmp
swollen
dcm
h
resin
wash
nmp
coupl
glutam
acid
via
c
carboxyl
acid
agit
resin
solut
fmocglu
oall
oh
equiv
hatu
equiv
n
ndiisopropylethylamin
dipea
equiv
nmp
resin
cap
wash
solut
ch
cl
acet
anhydridedipea
fmoc
protect
group
remov
treat
resinattach
peptid
piperidin
nmp
min
linear
precursor
peptid
construct
use
fmoc
chemistri
ad
respect
protect
amino
acid
equiv
hatu
equiv
dipea
equiv
nmp
give
linear
penta
peptideresin
c
termin
allyl
ester
glu
remov
treat
result
pentapeptid
pd
pph
equiv
chcl
acohnmethylmorpholin
argon
atmospher
gentl
shake
h
wash
dipeanmp
follow
wv
sodium
diethyldithiocarbam
trihydr
nmp
min
total
ml
onresin
cycliz
perform
remov
nfmoc
group
ly
activ
c
carboxyl
acid
glu
hatu
equiv
dipea
equiv
cleavag
peptid
resin
remov
protect
group
perform
agit
resinpeptid
trifluoroacet
acid
tfa
dcm
h
wash
tfadcm
acid
wash
concentr
et
ad
white
precipit
separ
precipit
freed
solvent
dissolv
water
purifi
prepar
revers
phase
hplc
use
gradient
mecnh
contain
tfa
mlmin
min
run
time
lyophil
give
compound
white
powder
mg
base
estim
load
peptideresin
linear
kngrg
kngrg
use
protocol
describ
except
gli
preload
rink
amid
mbha
resin
use
instead
glu
avoid
accompani
reactiv
function
group
assembl
last
amino
acid
fmoc
group
remov
ly
acetyl
linear
peptid
cleav
resin
describ
peptid
purifi
prepar
revers
phase
hplc
use
gradient
mecnh
contain
tfa
min
run
time
lyophil
give
compound
white
powder
mg
gener
proceduredipea
ad
solut
ngr
peptid
equiv
oregon
green
carboxyl
acid
succinimidyl
ester
isom
mg
mmol
equiv
nmp
result
reaction
mixtur
stir
h
room
temperatur
reaction
mixtur
precipit
pour
ml
diethyleth
filter
wash
diethyleth
result
etherfre
precipit
dissolv
water
purifi
prepar
revers
phase
hplc
gener
procedureaverag
mw
dspepeg
ch
cooh
n
gmol
solut
dspepeg
ch
cooh
mg
mmol
n
dcc
mg
mmol
hobt
mg
mmol
nmp
dipea
ad
stir
min
room
temperatur
peptid
equiv
ad
result
reaction
mixtur
allow
stir
overnight
ambient
temperatur
mixtur
powder
pour
diethyleth
ml
precipit
wash
diethyleth
dri
dri
powder
dissolv
meoh
chcl
purifi
chcl
meoh
eluent
concentr
et
ad
white
precipit
dspepeg
ch
cockngr
dspepeg
ch
cokngrg
separ
doxorubicin
encapsulationdox
load
ngrtarget
liposom
prepar
follow
dppc
mspc
dspepeg
cngr
molar
percent
ratio
prepar
describ
dri
film
hydrat
mm
citric
acid
ph
minut
yield
final
lipid
concentr
mgml
result
multilamellar
prepar
size
particl
size
determin
describ
encapsul
dox
extrud
liposom
carri
use
phgradient
load
protocol
describ
mayer
et
al
slight
modif
briefli
exterior
ph
extrud
liposom
titrat
sodium
carbon
solut
mm
creat
ph
gradient
acid
insid
liposom
incub
dox
dox
lipid
wt
ratio
pass
fine
spin
column
liposomeentrap
dox
determin
use
uvvi
spectrophotomet
dox
load
effici
consist
ltsl
use
method
releas
encapsul
dox
cngrltsl
function
temperatur
determin
measur
dequench
dox
fluoresc
releas
liposom
period
minut
use
cari
eclips
spectrofluorimet
equip
eclips
multicel
peltier
temperatur
control
eclips
kinet
softwar
varian
inc
excit
emiss
wavelength
nm
respect
sampl
liposom
ad
cuvett
contain
ml
hepe
buffer
equilibr
desir
temperatur
fluoresc
intens
measur
sec
interv
first
second
second
interv
remaind
ww
salin
ad
complet
disrupt
liposom
bilay
complet
releas
entrap
dox
percent
releas
calcul
assum
releas
releas
hepe
buffer
data
present
mean
percent
releas
n
cellular
bind
linear
cyclic
form
ngrog
assess
plate
cell
eightchamb
slide
labtekii
nunc
ny
concentr
cellswel
h
cell
wash
phosphatebuff
salin
pb
incub
complet
cultur
media
includ
serum
min
ckngreog
kngrgog
dilut
antibodi
alexa
fluor
obtain
abd
serotec
nc
final
concentr
slide
wash
twice
pb
min
fix
paraformaldehyd
min
mount
prolong
gold
antifad
reagent
dapi
invitrogen
imag
epifluoresc
microscop
zeiss
axio
ny
dose
ngr
provid
best
contrast
posit
neg
cell
rang
examin
dose
examin
intern
cell
incub
ckngreog
complet
cultur
media
minut
wash
twice
pb
place
complet
media
min
slide
fix
mount
cell
imag
use
method
epifluoresc
microscopi
laser
scan
confoc
fluoresc
microscop
zeiss
use
object
emiss
excit
spectra
set
manufactur
recommend
set
fluorophor
influenc
cycliz
ngr
peptid
affin
free
peptid
peptid
conjug
ltsl
studi
ckngre
peptid
assembl
use
manual
solid
phase
fmoc
peptid
chemistri
outlin
scheme
nfmocglu
oall
oh
select
anchor
site
cycliz
use
acid
hatu
equiv
base
amino
acid
use
peptid
coupl
piperidin
nmp
use
deprotect
fmoc
group
nterminu
orthogon
deprotect
c
allyl
ester
glu
use
pd
pph
chcl
acohnmethylmorpholin
resin
cycliz
carri
coupl
acid
glu
ly
hatu
high
dilut
remov
cyclic
peptid
resin
deprotect
perform
use
tfa
dichloromethan
crude
peptid
concentr
purifi
prepar
revers
phase
hplc
column
obtain
white
powder
pure
yield
linear
kngrg
synthes
use
methodolog
except
fmocgli
preload
rink
amid
resin
scheme
use
instead
glu
avoid
side
chain
reactiv
function
group
overal
product
yield
obtain
puriti
free
amin
ly
residu
use
introduc
fluoresc
label
og
equiv
obtain
compound
respect
scheme
compound
purifi
prepar
revers
phase
hplc
use
column
give
yellow
powder
yield
respect
ngr
peptid
conjug
dspepeg
ch
cooh
give
compound
scheme
case
progress
reaction
monitor
malditofm
almost
dspepeg
ch
cooh
observ
compound
purifi
size
exclus
chromatographi
use
sephadex
swollen
elut
chcl
meoh
peak
expect
mz
ratio
compound
yield
yield
confirm
malditofm
experi
figur
minor
peak
consist
sodium
salt
mz
seen
major
peak
spectra
ngrtarget
ltsl
synthes
particl
size
nm
kngrgltsl
nm
ckngreltsl
dox
encapsul
ckngretarget
ltsl
liposom
particl
size
nm
evalu
vitro
bind
ngr
peptid
human
carcinoma
cell
ckngre
conjug
fluorophor
og
visual
via
epifluoresc
microscopi
ckngreog
antibodi
incub
cell
ckngreog
clearli
demonstr
bind
cell
figur
e
wherea
agent
display
minim
bind
cell
figur
antibodi
fluoresc
membraneassoci
dispers
across
cell
surfac
addit
membran
fluoresc
intens
punctuat
fluoresc
observ
cell
incub
ckngreog
figur
suggest
intern
peptid
higher
magnif
figur
f
local
ckngreog
appear
similar
except
bright
punctuat
signal
associ
ckngreog
intens
membran
associ
fluoresc
cellular
distribut
similar
longer
incub
period
hour
investig
linear
kngrgog
figur
display
similar
cellular
distribut
ckngreog
figur
punctuat
fluoresc
albeit
lower
overal
fluoresc
intens
ckngreog
distribut
similar
imag
live
cell
order
elucid
caus
punctuat
fluoresc
ckngreog
cell
incub
ckngreog
minut
incub
reduc
endocytosi
accumul
cytoplasm
vesicl
contrast
mark
cellular
intern
figur
figur
minim
uptak
ckngreog
furthermor
punctuat
fluoresc
insid
cell
determin
confoc
microscopi
shown
figur
intern
ckngreog
demonstr
pattern
consist
endosom
uptak
investig
bind
affin
free
ngr
peptid
ngrtarget
ltsl
ec
valu
determin
use
flow
cytometri
cell
approxim
cell
posit
antibodi
indic
presenc
shown
figur
ckngreog
demonstr
greater
affin
cell
ec
linear
kngrgog
ec
similarli
shown
figur
ltsl
conjug
ckngre
ec
greater
avid
ltsl
conjug
linear
kngrg
ec
experi
repeat
twice
similar
result
data
demonstr
cyclic
ngr
much
greater
affin
linear
ngr
peptid
bind
constant
suffici
biolog
applic
furthermor
multival
present
ngr
peptid
surfac
liposom
increas
affin
free
peptid
base
concentr
ngr
assum
liposom
would
ngr
ligand
outer
surfac
ngrltsl
correspond
total
ngr
ligand
per
liposom
sinc
mani
ngr
per
liposom
affin
base
particl
basi
actual
increas
ckngre
ckngretarget
ltsl
due
multival
present
cngr
temperatur
depend
releas
dox
ckngretarget
ltsl
investig
fluoresc
dequench
assay
shown
figur
dox
rapidli
releas
releas
sec
minim
releas
releas
kinet
similar
publish
report
unmodifi
ltsl
slightli
differ
formul
well
untarget
ltsl
ident
composit
hepe
buffer
plasma
novel
perman
cycliz
ngr
peptid
synthes
evalu
bind
cancer
cell
synthet
strategi
result
suffici
yield
puriti
respect
ckngre
perman
cycliz
ngr
peptid
greater
affin
linear
form
free
peptid
surfac
liposom
increas
affin
due
cycliz
similar
peptid
exhibit
improv
affin
conform
constrain
ngrltsl
greater
avid
free
ngrog
would
expect
due
multival
present
ngr
ligand
surfac
liposom
cycliz
peptid
design
employ
c
carboxyl
acid
glu
ring
closur
process
ly
obtain
number
chemic
bond
ring
origin
identifi
common
cyclic
cngrc
peptid
cycliz
disulfid
bridg
addit
modif
ring
size
ngr
flank
residu
may
improv
bind
affin
specif
cyclic
ngr
peptid
previou
report
demonstr
util
ngr
peptid
drug
deliveri
molecular
imag
work
employ
linear
disulfid
bridg
form
peptid
surfac
liposom
target
vehicl
cyclic
ngr
peptid
form
disulfid
bridg
may
develop
addit
disulfid
bridg
adjac
peptid
render
ligand
ineffect
new
cycliz
version
ngr
report
herein
avoid
potenti
pitfal
retain
suffici
bind
avid
ec
target
vitro
contrast
method
attach
linear
ngr
peptid
liposom
report
pastorino
et
al
involv
chemic
attach
peptid
presynthes
liposom
first
synthes
peglipid
cyclic
ngr
target
moieti
synthes
liposom
although
previous
report
method
advantag
simplic
overal
faster
synthesi
method
offer
favor
control
liposom
composit
reduc
manipul
drug
load
reproduc
knowledg
may
first
report
tumor
vascular
target
ltsl
tumor
target
temperatur
sensit
liposom
report
target
liposom
may
also
combin
emerg
heat
sourc
high
intens
focus
ultrasound
imag
technolog
monitor
drug
deliveri
combin
tumor
vascular
target
temperatur
trigger
drug
releas
liposom
potenti
improv
therapeut
efficaci
slow
transit
time
liposom
tumor
vasculatur
improv
drug
releas
improv
total
drug
accumul
tumor
treat
metastat
tumor
subject
hyperthermia
target
tumor
vasculatur
liposom
advantag
tradit
tumor
cell
target
immunoliposom
requir
slow
process
extravas
subsequ
penetr
bind
cellular
uptak
occur
contrast
tumor
cell
antigen
tumor
vascular
antigen
immedi
avail
bind
directli
intraven
administr
furthermor
target
angiogen
tumor
vasculatur
ubiquit
approach
applic
solid
tumor
requir
overexpress
tumor
cell
specif
antigen
often
limit
particular
subtyp
tumor
temperatur
trigger
drug
releas
ltsl
demonstr
excel
tumor
control
preclin
model
localregion
therapi
limit
abil
treat
widespread
metastat
diseas
promis
preclin
result
ngrtarget
nontherm
sensit
liposom
metastat
model
suggest
ngrtarget
thermal
sensit
formul
report
herein
may
abl
provid
excel
localregion
control
tumor
target
hyperthermia
well
improv
therapi
ngrtarget
unheat
metastat
diseas
report
synthesi
novel
cyclic
ngr
ligand
ckngre
evalu
vitro
bind
cancer
cell
ckngre
synthesi
verifi
nmr
mass
spectral
techniqu
result
high
yield
puriti
vitro
fluoresc
microscopi
studi
reveal
bind
ckngreog
cell
minim
bind
cell
membran
local
ckngreog
similar
antibodi
except
bright
punctuat
signal
associ
activ
intern
ckngreog
ckngre
ligand
display
greater
affin
cancer
cell
linear
kngrg
affin
similarli
improv
cyclic
linear
ngr
peptid
attach
surfac
ltsl
ckngretarget
ltsl
rapidli
releas
sec
doxorubicin
minim
releas
result
studi
signific
demonstr
improv
avid
ngrtarget
ltsl
without
limit
disulfid
bridg
fluoresc
microscopi
evalu
vitro
bind
antibodi
top
row
b
c
ckngreog
bottom
row
e
f
cell
b
c
e
f
cell
green
signal
ckngreog
antibodi
blue
signal
nuclear
stain
agent
dapi
imag
ab
de
acquir
ident
exposur
time
display
consist
compar
bind
cell
bar
equal
b
e
c
f
epifluoresc
microscopi
evalu
vitro
intern
ckngreog
cell
b
green
signal
ckngreog
blue
signal
nuclear
stain
agent
dapi
imag
acquir
ident
exposur
time
display
consist
window
level
bar
equal
releas
dox
ckngretarget
ltsl
percent
releas
calcul
assum
releas
releas
hepe
buffer
